Notice: This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends MGEN vs. PSNL, BDSX, XGN, BNR, ENZ, PMD, OPGN, BGLC, MDXH, and FRESShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Personalis (PSNL), Biodesix (BDSX), Exagen (XGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), Psychemedics (PMD), OpGen (OPGN), BioNexus Gene Lab (BGLC), MDxHealth (MDXH), and Fresh2 Group (FRES). Miragen Therapeutics vs. Personalis Biodesix Exagen Burning Rock Biotech Enzo Biochem Psychemedics OpGen BioNexus Gene Lab MDxHealth Fresh2 Group Personalis (NASDAQ:PSNL) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Which has more risk & volatility, PSNL or MGEN? Personalis has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Does the media favor PSNL or MGEN? In the previous week, Personalis had 13 more articles in the media than Miragen Therapeutics. MarketBeat recorded 13 mentions for Personalis and 0 mentions for Miragen Therapeutics. Personalis' average media sentiment score of 0.34 beat Miragen Therapeutics' score of 0.00 indicating that Personalis is being referred to more favorably in the media. Company Overall Sentiment Personalis Neutral Miragen Therapeutics Neutral Do analysts recommend PSNL or MGEN? Personalis presently has a consensus target price of $7.31, indicating a potential upside of 27.17%. Given Personalis' stronger consensus rating and higher possible upside, research analysts clearly believe Personalis is more favorable than Miragen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Personalis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Miragen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in PSNL or MGEN? 61.9% of Personalis shares are owned by institutional investors. 4.1% of Personalis shares are owned by insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer PSNL or MGEN? Miragen Therapeutics received 150 more outperform votes than Personalis when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 66.86% of users gave Personalis an outperform vote. CompanyUnderperformOutperformPersonalisOutperform Votes11766.86% Underperform Votes5833.14% Miragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% Is PSNL or MGEN more profitable? Personalis has a net margin of -104.52% compared to Miragen Therapeutics' net margin of -1,393.50%. Personalis' return on equity of -66.07% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Personalis-104.52% -66.07% -41.34% Miragen Therapeutics -1,393.50%-141.66%-88.74% Which has better earnings and valuation, PSNL or MGEN? Miragen Therapeutics has lower revenue, but higher earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPersonalis$87.49M4.64-$108.30M-$1.68-3.42Miragen Therapeutics$4.46M16.67-$41.87M-$20.09-0.95 SummaryPersonalis beats Miragen Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.37M$2.84B$5.14B$9.08BDividend YieldN/A15.63%5.09%4.23%P/E Ratio-1.7916.0290.1317.19Price / Sales16.67274.981,116.25117.05Price / CashN/A472.1143.1037.85Price / Book2.815.194.784.78Net Income-$41.87M-$32.86M$120.31M$225.60M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$19.03+1.6%N/A-10.9%$74.37M$4.46M-1.7945Gap DownHigh Trading VolumePSNLPersonalis3.977 of 5 stars$3.78-1.0%$6.81+80.2%+280.8%$267.06M$73.48M-2.27400Analyst ForecastNews CoverageGap UpBDSXBiodesix2.5549 of 5 stars$1.33-0.7%$3.06+130.1%-4.8%$193.47M$65.56M-3.44220XGNExagen4.6639 of 5 stars$6.01+4.0%$7.00+16.5%+197.7%$106.02M$52.55M-6.14220High Trading VolumeBNRBurning Rock Biotech1.977 of 5 stars$6.75+0.3%N/A-11.1%$69.15M$510.89M-2.241,390Positive NewsGap DownENZEnzo Biochem0.7695 of 5 stars$1.02flatN/A-45.5%$53.29M$31.91M0.00520Earnings ReportAnalyst ForecastPMDPsychemedics1.4031 of 5 stars$2.67-1.8%N/A-7.0%$15.73M$22.10M0.00140Insider TradePositive NewsGap DownHigh Trading VolumeOPGNOpGenN/A$1.07-3.6%N/A-82.7%$8.95M$3.42M0.00100Analyst ForecastNews CoverageGap DownBGLCBioNexus Gene LabN/A$0.25-3.6%N/A-59.5%$4.51M$9.26M0.0030Positive NewsGap UpMDXHMDxHealth1.8991 of 5 stars$2.46+2.5%$7.00+184.6%-93.9%$3.84M$84.71M-1.58300News CoverageFRESFresh2 GroupN/A$1.40+7.7%N/A-86.8%$1.26M$16.98M0.0075Positive NewsGap Down Related Companies and Tools Related Companies Personalis Alternatives Biodesix Alternatives Exagen Alternatives Burning Rock Biotech Alternatives Enzo Biochem Alternatives Psychemedics Alternatives OpGen Alternatives BioNexus Gene Lab Alternatives MDxHealth Alternatives Fresh2 Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGEN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
